Summary: In a study published in Molecular Cancer Therapeutics, Catalent Biologics experts share the results of preclinical studies on their HER2-targeted ADC, CAT-01-106.

Summary: Hear Penelope Drake, Director of R&D for Catalent Biologics, present on the demonstrated success of SMARTag® across several therapeutic modalities in this on-demand webinar.

Summary: Hear from Mario Gargiulo, Catalent’s Region President, Biologics, Europe in this fireside chat interview with Dan Stanton, Editor and Founder, Bioprocess Insider.

Summary: In this executive summary, industry experts share case studies of how they’ve adapted to increasingly expedited regulatory reviews.

Summary: Bernie Clark, VP of Marketing and Strategy for Catalent Biologics, discusses the challenges and risks associated with this undertaking and the collaboration and innovation necessary to help combat coronavirus in this Q&A.

Summary: Catalent Biologics presents a case study on the investigational COVID-19 therapeutic candidate, lenzilumab, and its development from gene to late stage clinical trials.

Summary: Enzymes can be challenging to express and scale up to become biologic therapies.  In order to develop their optimized tissue plasmigen activator (tPA) to treat patients with hemorrhagic stroke...

Summary: Which 11 biotech startups stand out from the pack that have launched in 2020? Watch the Endpoints 11 - Startups to Watch Awards, a virtual event celebrating innovative science and entrepreneurship.

Summary: Hear Catalent Biologics Region President, address challenges in manufacturing scale-up and discuss how partnerships are enabling pharma companies of all sizes to meet unprecedented timelines as they race toward delivering vaccines to patients worldwide.

Summary: Download this webinar to learn how our RED-106 noncleavable maytansine linker-payload is well-tolerated, offering wider therapeutic windows compared to other technologies.